172 related articles for article (PubMed ID: 26927629)
21. The effect of testosterone treatment on prostate histology and apoptosis in men with late-onset hypogonadism.
Efesoy O; Apa D; Tek M; Çayan S
Aging Male; 2016 Jun; 19(2):79-84. PubMed ID: 26927833
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
23. Marketing and Testosterone Treatment in the USA: A Systematic Review.
Bandari J; Ayyash OM; Emery SL; Wessel CB; Davies BJ
Eur Urol Focus; 2017 Oct; 3(4-5):395-402. PubMed ID: 29174614
[TBL] [Abstract][Full Text] [Related]
24. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.
Leibowitz RL; Dorff TB; Tucker S; Symanowski J; Vogelzang NJ
BJU Int; 2010 May; 105(10):1397-401. PubMed ID: 19912179
[TBL] [Abstract][Full Text] [Related]
25. Late-onset hypogonadism: Reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy.
Sesti F; Pofi R; Minnetti M; Tenuta M; Gianfrilli D; Isidori AM
Andrology; 2020 Nov; 8(6):1614-1627. PubMed ID: 32737921
[TBL] [Abstract][Full Text] [Related]
26. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
27. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
28. Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus - a series of case reports.
Saad F; Yassin A; Almehmadi Y; Doros G; Gooren L
Aging Male; 2015; 18(3):164-8. PubMed ID: 26075537
[TBL] [Abstract][Full Text] [Related]
29. Testosterone replacement therapy is associated with an increased risk of urolithiasis.
McClintock TR; Valovska MI; Kwon NK; Cole AP; Jiang W; Kathrins MN; Bhojani N; Haleblian GE; Koehlmoos T; Haider AH; Basaria S; Trinh QD
World J Urol; 2019 Dec; 37(12):2737-2746. PubMed ID: 30903351
[TBL] [Abstract][Full Text] [Related]
30. Blood donation and testosterone replacement therapy.
Chin-Yee B; Lazo-Langner A; Butler-Foster T; Hsia C; Chin-Yee I
Transfusion; 2017 Mar; 57(3):578-581. PubMed ID: 28150363
[TBL] [Abstract][Full Text] [Related]
31. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices.
Miner M; Canty DJ; Shabsigh R
Postgrad Med; 2008 Sep; 120(3):130-53. PubMed ID: 18824832
[TBL] [Abstract][Full Text] [Related]
32. Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men.
Cole AP; Hanske J; Jiang W; Kwon NK; Lipsitz SR; Kathrins M; Learn PA; Sun M; Haider AH; Basaria S; Trinh QD
BJU Int; 2018 May; 121(5):811-818. PubMed ID: 29383868
[TBL] [Abstract][Full Text] [Related]
33. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.
Liao CH; Wu YN; Lin FY; Tsai WK; Liu SP; Chiang HS
Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307
[TBL] [Abstract][Full Text] [Related]
34. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
35. Effects of testosterone replacement therapy on nocturia and quality of life in men with hypogonadism: a subanalysis of a previous prospective randomized controlled study in Japan.
Shigehara K; Konaka H; Koh E; Izumi K; Kitagawa Y; Mizokami A; Nakashima T; Shimamura M; Iwamoto T; Namiki M
Aging Male; 2015; 18(3):169-74. PubMed ID: 26075538
[TBL] [Abstract][Full Text] [Related]
36. Trends in Testosterone Prescription and Public Health Concerns.
Gabrielsen JS; Najari BB; Alukal JP; Eisenberg ML
Urol Clin North Am; 2016 May; 43(2):261-71. PubMed ID: 27132584
[TBL] [Abstract][Full Text] [Related]
37. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
Blick G; Khera M; Bhattacharya RK; Kushner H; Miner MM
Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
[TBL] [Abstract][Full Text] [Related]
38. Testosterone replacement therapy for late-onset hypogonadism.
Cunningham GR
Nat Clin Pract Urol; 2006 May; 3(5):260-7. PubMed ID: 16691239
[TBL] [Abstract][Full Text] [Related]
39. The impact of drug reimbursement policy on rates of testosterone replacement therapy among older men.
Piszczek J; Mamdani M; Antoniou T; Juurlink DN; Gomes T
PLoS One; 2014; 9(7):e98003. PubMed ID: 25029014
[TBL] [Abstract][Full Text] [Related]
40. Androgen replacement in men undergoing treatment for prostate cancer.
Rhoden EL; Averbeck MA; Teloken PE
J Sex Med; 2008 Sep; 5(9):2202-8. PubMed ID: 18638000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
